BAYRHO-D FULL DOSE Rx
Generic Name and Formulations:
Rho(D) immune globulin human 300mcg; for IM inj; solvent/detergent treated.
- Cabozantinib Yields Similar QoL Outcomes to Everolimus in Renal Cell Carcinoma
- Cabozantinib May Be Effective for Acute Myeloid Leukemia
- AZD9291 Highly Active in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer
- Recommended Immunization Schedule for Ages 0 to 18 Years
- Melanoma Treatment Regimens
- Ovarian Cancer Treatment Regimens
Indications for BAYRHO-D FULL DOSE:
Preventing Rho(D) sensitization in nonsensitized Rho(D) negative or Du negative patients to the Rho(D) factor, following pregnancy or accidental transfusion.
Each vial or syringe (approx. 300mcg) prevents sensitization to a volume of up to 15mL of Rh positive red blood cells. Administer IM at 28 weeks of gestation, within 72 hours of an Rh incompatible delivery, miscarriage, abortion, or transfusion accident.
Rho(D) positive patients. Pregnancy (Cat.C).
Live vaccines. Have epinephrine available.
Full Dose (single-dose syringes and vials)—1, 10; Mini-Dose (single-dose syringes)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma